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Abstract
Background: Limb Girdle Muscular Dystrophy (LGMD), caused by defective α-dystroglycan (α-DG) glycosylation,
was recently associated with mutations in Isoprenoid synthase domain-containing (ISPD) and GDP-mannose
pyrophosphorylase B (GMPPB) genes. The frequency of ISPD and GMPPB gene mutations in the LGMD population
is unknown.
Methods: We investigated the contributions of ISPD and GMPPB genes in a cohort of 174 Italian patients with LGMD,
including 140 independent probands. Forty-one patients (39 probands) from this cohort had not been genetically
diagnosed. The contributions of ISPD and GMPPB were estimated by sequential α-DG immunohistochemistry (IHC)
and mutation screening in patients with documented α-DG defect, or by direct DNA sequencing of both genes when
muscle tissue was unavailable.
Results: We performed α-DG IHC in 27/39 undiagnosed probands: 24 subjects had normal α-DG expression, two had a
partial deficiency, and one exhibited a complete absence of signal. Direct sequencing of ISPD and GMPPB revealed two
heterozygous ISPD mutations in the individual who lacked α-DG IHC signal: c.836-5 T > G (which led to the deletion of
exon 6 and the production of an out-of-frame transcript) and c.676 T > C (p.Tyr226His). This patient presented with
sural hypertrophy and tip-toed walking at 5 years, developed moderate proximal weakness, and was fully ambulant at
42 years. The remaining 12/39 probands did not exhibit pathogenic sequence variation in either gene.
Conclusion: ISPD mutations are a rare cause of LGMD in the Italian population, accounting for less than 1 % of the
entire cohort studied (FKRP mutations represent 10 %), while GMPPB mutations are notably absent in this patient
sample. These data suggest that the genetic heterogeneity of LGMD with and without α-DG defects is greater than
previously realized.
Keywords: Isoprenoid synthase domain-containing gene, GDP-mannose pyrophosphorylase B, Limb Girdle Muscular
Dystrophy, α-dystroglycan glycosylation
Background
Limb girdle muscular dystrophies (LGMDs) are a hetero-
geneous group of inherited progressive muscle disorders
characterized by progressive shoulder and pelvic gir-
dle muscle weakness variably associated with cardiac,
respiratory, and cognitive involvement [1]. The num-
ber of genes involved in these disorders has exponen-
tially increased in recent years, and now up to 30
different forms have been described, inherited both
with autosomal dominant (7 forms) and autosomal
recessive (23 forms) patterns [2].
In particular, a high number of genes involved in
α-dystroglycan (α-DG) glycosylation have been associ-
ated with LGMD. α-DG is a highly glycosylated core
component of the dystrophin glycoprotein complex, and
forms a link between the sarcolemma and the extracellu-
lar matrix [3]. To date, mutations in 14 genes [4–18], all
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coding for putative or demonstrated glycosyltransferase,
have been associated with muscular dystrophies (referred
to as secondary dystroglycanopathies) [19], while only a
couple of cases have been associated with mutations in
DAG1, the gene that encodes both α-dystroglycan and
β-dystroglycan [20, 21]. Dystroglycanopathies are char-
acterised by a broad variety of clinical phenotypes,
ranging from congenital muscular dystrophy (CMD),
with or without brain and eye involvement as Walker-
Warburg syndrome (WWS) and muscle eye brain dis-
ease (MEB), to LGMD, as summarised by Godfrey et al.
[22]. Mutations in most of these genes are mainly associ-
ated with severe or congenital conditions, with few not-
able exceptions: FKRP mutations account for a variable
proportion of LGMD depending on ethnic background
(from 6 % in the Italian population [1, 23] to 38 % in the
Danish population [24]). On the other hand, LGMD
phenotypes caused by mutations in POMT1 (LGMD2K)
[25], FKTN (LGMD2L) [26], POMT2 (LGMD2N) [27],
POMGNT1 (LGMD2O) [22], DAG1 [21], and DPM3
[10] have been reported in a very limited number of
patients.
ISPD, a gene located on chromosome 7p21, encodes
the Isoprenoid synthase domain-containing protein and
has been implicated in the initial step of the O-
mannosylation of α-DG. Mutations in this gene were
first identified within the most severe spectrum of
dystroglycanopathies, WWS and MEB cases [13, 14],
although more recently they have also been associated
with milder phenotypes [28, 29]. In a paediatric cohort
of dystroglycanopathies with British and Turkish back-
ground, ISPD mutations have been found to cause
LGMD in seven probands, including four LGMD cases
with normal cognitive development (LGMD – no MR);
two LGMD cases with cerebellar involvement (LGMD-
CRB); and one case of LGMD with mental retardation,
but without structural brain abnormalities (LGMD-MR)
[28]. ISPD mutations were also detected in two Italian
LGMD families that presented with disease onset during
the first two decades of life, late motor impairment, and
no functional or structural brain involvement [28].
Muscle biopsy revealed dystrophic features and α-DG
reduction at immunohistochemistry [28, 29]. According
to this description, forms of LGMD caused by mutations
in ISPD are described as LGMD2S [2]. Intra-familial
variability has also been described [30].
ISPD mutations account for 9–11 % of the most severe
dystroglycanopathy variants (comprising CMD, WWS,
and cobblestone lyssencephaly) in three large cohorts
from different ethnic backgrounds [13, 14, 17]. The preva-
lence of ISPD mutations has not yet been estimated in
LGMD cohorts: at this time, only 12 patients with ISPD
mutation and this phenotype have been described. Similar
considerations apply to disease phenotypes caused by
GMPPB mutations, initially shown to be causally linked to
MEB/FCMD-like syndrome [16, 31], and more recently to
a wider phenotypic spectrum that includes infantile phe-
notypes with mental retardation [16] and adult-onset
LGMD with normal cognition [32].
The aim of this study is to establish the prevalence of
ISPD and GMPPB mutations within an Italian cohort of
LGMD patients.
Methods
Patient selection and characterization
From a cohort of 174 Italian LGMD patients (140 families),
all followed at a single neuromuscular centre, we selected
41 patients (39 families) without a molecular diagnosis.
Written informed consent was obtained (and preserved in
original) from all patients or their caregivers at first
evaluation, with explicit consent to future use for research
purposes, in accordance with the Declaration of Helsinki.
This protocol was approved by the Research Ethics Board
of IRCCS Foundation Ca’ Granda Ospedale Maggiore
Policlinico. The patients have been previously screened for
the following genes: MYOT, LMNA, CAV3, DNAJB6,
and TNPO3, if autosomal dominant transmission was
supported by family history; CAPN3, DYSF, SGCA,
SGCB, SGCG, SGCD, FKRP, ANO5, FKTN, and LAMA2
in sporadic or autosomal recessive cases.
LARGE, POMT1, POMT2, POMGnT1 were also screened
in selected cases.
Patients were defined as affected with LGMD if they
fulfilled the following criteria: clinical phenotype charac-
terised by progressive muscle weakness and wasting af-
fecting primarily the shoulder girdle and pelvic muscles,
in keeping with the diagnostic criteria for LGMD [33];
and dystrophic features at muscle biopsy. All patients
had undergone systematic clinical characterisation, in-
cluding comprehensive neurological [Medical Research
Council (MRC) and functional scales], cardiac (electro-
cardiogram and echocardiogram), and respiratory (spir-
ometry and nocturnal saturimetry) assessments. Data
about clinical and familial history were also collected.
All specimens were obtained from the Skeletal Muscle,
Peripheral Nerve, DNA and Cell Line Bank of the Neuro-
muscular Unit, Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, University of Milan. Written in-
formed consent was obtained and preserved in the
original form from all individuals or their caregivers when
primary diagnostic procedures were performed, with ex-
plicit consent for future use for research purposes, accord-
ing to the Declaration of Helsinki.
Muscle biopsy analysis
All probands had previously undergone a skeletal muscle
biopsy during the period between 1975 and 2014. Muscle
samples were frozen in isopentane, cooled in liquid
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nitrogen, and stained histochemically according to stand-
ard procedures [34]. We reviewed muscle biopsies from
cases without a genetic characterization, which included
data about α-DG immunohistochemical (IHC) analysis
(performed with the clone VIA4-1; Merck Millipore, UK).
In muscle samples in which α-DG IHC had not been
conducted previously, this study was performed using the
antibody cited above if a muscle tissue sample was
available.
Molecular analysis
Genomic DNA was extracted from peripheral blood
samples according to standard procedures (Flexi Gene
DNA Handbook, Qiagen).
ISPD and GMPPB analysis were performed in patients
who exhibited α-DG deficiency at muscle IHC and in
patients who had LGMD inclusion criteria, but whose
muscle sample was unavailable at the time of this inves-
tigation. Mutations in FKRP, the most common LGMD
gene involved in α-DG glycosylation [1, 32, 35], were
also ruled out for the first group of patients.
All exons and flanking intronic regions were directly
sequenced using an ABI PRISM 3100 XL Genetic
Analyzer (Applied Biosystems) and previously published
primer [13, 16].
The pathogenic nature of new mutations was con-
firmed by screening 100 healthy control subjects. The
intronic mutation that leads to abnormal mRNA splicing
was investigated through transcript analysis. The paren-
tal origin of each mutation was assessed through analysis
of parental genomic DNA, when available. Amino acid
conservation was confirmed by comparison with se-
quences from different species.
We isolated mRNA from muscle tissue using Eurozol;
the cDNA was produced through reverse transcription
polymerase chain reaction (Ready-To-Go RT-PCR kit,
Amersham Pharmacia) and analyzed by amplification,
cloning, and sequencing. Mutations were named ac-
cording to the Leiden Muscular Dystrophy database
(www.dmd.nl).
Results
Relative frequency of ISPD and GMPBB mutations in an
Italian cohort
Among a single-centre cohort of 174 Italian LGMD
patients (140 probands), 41 patients (39 probands) were
without a genetic diagnosis. For 12/39 probands, we dir-
ectly analyzed ISPD and GMPPB because muscle biopsy
samples were unavailable for α-DG IHC analysis: none
contained mutations. For 27/39 probands with avail-
able muscle biopsy, we performed α-DG IHC analysis,
followed by ISPD and GMPPB sequencing in cases
that exhibited any glycosylation defect: of 27 individuals,
24 had normal muscle α-DG expression, two had a partial
deficiency, and one exhibited a complete absence of signal.
The latter three cases were analysed for FKRP and
GMPPB showing wild-type sequences. Only one of them
had ISPD-causative mutations. Noteworthy, this latter
proband was the only case with a muscle biopsy that
exhibited complete absence α-DG labelling (Fig. 1).
Including this new case, the 102/140 probands with a
confirmed genetic diagnosis of LGMD had mutations in
the following genes: 2/102 (2 %) LMNA, 6/102 (6 %)
CAV3, 29/102 (28 %) CAPN3, 27/102 (25 %) DYSF, 5/
102 (5 %) SGCG, 12/102 (12 %) SGCD, 5/102 (5 %)
SGCB, 1/102 (1 %) SGCE, 8/102 (8 %) FKRP 5/102 (5 %)
ANO5, and 1/102 (1 %) LAMA2. The molecular data of
these patients are listed in a separate table [see Additional
file 1]. Overall, ISPD mutations account for 0.9 % of genet-
ically characterized LGMD probands (Fig. 2a). Among our
paediatric LGMD cohort, defined as patients with disease
onset before 10 years of age (33 patients; 27 probands)
ISPD mutations account for 4 % of cases. Relative
frequencies in the paediatric onset population are indi-
cated in Fig. 2b; sarcoglycanopathies (51 %), calpaino-
pathies (19 %), and LGMD2I (11 %) are the most
frequent forms.
Molecular analysis
The ISPD-mutated patient carried two compound
heterozygous mutations (Fig. 3a). The first mutation
(c.676 T > C; p.Tyr226His) was a missense substitution
in exon 3. Vuillaumier-Barrot et al. reported this muta-
tion previously [17] in a heterozygotic foetal case af-
fected with cobblestone lissencephaly; it was associated
with a large deletion involving exons 4 through 6. The
concerned amino acid is highly conserved among
species. The second mutation (c.836-5 T > G) was a
novel intronic substitution in IVS5. Its effect was in-
vestigated through transcript analysis, which revealed
the production of two different transcripts: the wild-
type transcript, and a shorter transcript corresponding
to an isoform with lower molecular weight. cDNA
cloning demonstrated that the smaller isoform corre-
sponds to a transcript in which the deletion of exon 6
results in the production of an out-of-frame transcript
(Fig. 3b). No alternative splicing could be demon-
strated because the full-length transcript is completely
encoded by the other allele, which contains a missense
mutation.
Clinical findings
The only patient with a mutation in ISPD was a male
who had been followed in our neuromuscular unit since
he was 5 years old. He was referred to our centre in the
late 1970s because of tip-toed walking. His family history
was negative for neuromuscular conditions. Both parents
were of Sicilian ancestry, and no consanguinity was
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Fig. 2 Relative frequency of ISPD mutations. a The relative frequency of different mutations in the entire sample. ISPD mutations account for
approximately 1 % of the probands. b The relative frequencies of different mutations in the sample of patients younger than 10 years old. ISPD
mutations account for 4 % of the probands
Fig. 1 Patient selection for ISPD analysis and mutation rate. α-DG IHC analysis in undiagnosed patients revealed that α-DG was reduced in 3/27
individuals (11 % of our sample). One of three patients exhibited an ISPD mutation. *Molecular screening was performed according to clinical and
bioptical characteristics
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reported. The patient’s prenatal history, delivery, and
psycho-motor development were unremarkable. At the
time of his first evaluation, neurological examination re-
vealed only mild sural hypertrophy. Muscle strength was
normal overall, with the exception of mild weakness at
the pelvic girdle with positive Gowers’ sign. Creatine
kinase levels ranged from 630 to 1200 IU/L (normal
values <200 IU/L). Neurophysiological investigation re-
vealed signs of mild myopathy at needle examination.
The patient underwent a quadriceps muscle biopsy,
which indicated a dystrophic process (Fig. 4). Consider-
ing these clinical and morphological findings, a diagnosis
of Becker muscular dystrophy was initially supposed;
however, later IHC analyses and Western blotting with
monoclonal antibodies directed against dystrophin
(Novocastra, 28 Newcastle Upon Tyne, UK) did not re-
veal any abnormalities. Furthermore, IHC analysis of
caveolin-3 (Transduction Laboratories, Lexington, KY)
and sarcoglycans (Transduction Laboratories, Lexington,
KY) demonstrated normal staining. Dysferlin Western
blot (Novocastra antibody) did not demonstrate any re-
duction of protein.
The patient’s motor performance has been stable
since the age of 14 years, when the patient first com-
plained of running difficulty and muscle cramps during
exercise. Over the following decades, muscle weakness
demonstrated a progressive course. At his last clinical
examination, at the age of 42 years, he showed mild
weakness at the neck flexors (MRC: 4) with moderate
proximo-distal weakness at all four limbs (MRC: del-
toids 3, brachial biceps 4, triceps 3, wrist extensors/
flexors 4, sartorius 2, hip extra- and intra-rotators 3,
quadriceps 3, tibialis anterior 4). He had universally de-
creased deep tendon reflexes, myopathic facies, bilateral
scapular winging, and mild scoliosis. He walked with a
waddling-type gait, and was able to climb stairs with
double support. Ability to run had been lost (he walked
10 meters in 6.19 seconds). Regarding pulmonary in-
volvement, spirometry indicated that his forced vital
capacity was 3.35 L (71 %); nocturnal oxygen saturation
was normal. His cardiac evaluation (echocardiogram)
documented a right bundle branch block without any
abnormalities of contractility. No cognitive impairment
was observed (the patient acquired a degree in Engin-
eering and worked as an engineer). We were unable to
perform magnetic resonance imaging studies because of
the patient’s severe claustrophobia.
Discussion
Mutations in genes involved in α-DG glycosylation have
been associated with a broad spectrum of disorders
ranging from severe CMD to milder LGMD phenotypes
[36]. An increasing number of genes involved in these
disorders have been discovered recently, enlarging the
Fig. 3 ISPD molecular analysis. a Electropherograms depicting the missense mutation c.676 T > C and the intronic substitution c.836-5 T > G.
b mRNA analysis reveals the production of two different transcripts: the wild-type transcript, and a shorter transcript that corresponds to an isoform
with a lower molecular weight. cDNA cloning demonstrated that the latter isoform corresponds to an isoform lacking exon 6
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spectrum of molecular heterogeneity of dystroglycanopa-
thies. Among them, ISPD and GMPPB appear to follow
FKRP as relevant genes in the LGMD population, ac-
cording to earlier reports [16, 28].
It should be kept in mind that variations in relative
frequency for a gene may be population-dependent. This
is the case for the FKRP gene, which accounts for ap-
proximately 6 % of LGMD in Italian patients [1, 23],
compared with 19 % among the British population [37]
and 38 % among the Danish population [24]. Regarding
other genes responsible for secondary dystroglycanopa-
thies, only sporadic cases with LGMD phenotype have
been reported thus far [10, 16, 21, 25–28]. In particular,
ISPD mutations appear to be responsible for a relatively
high proportion of dystroglycanopathies within the most
severe clinical spectrum [13, 14, 17], although they have
also been described in a few LGMD cases [28–30].
We analysed a large cohort of Italian LGMD patients
in order to estimate the frequency of ISPD and GMPPB
mutations and their associated clinical picture. In our
LGMD sample, only a small proportion of undiagnosed
cases (3/27, 11 %) exhibited reduction of α-DG staining.
This finding suggests that if we exclude mutations in the
FKRP gene, the other forms associated with defects of
α-DG glycosylation are much more rare. Forms of
LGMD caused by mutations in ISPD were also rare
overall in our cohort, as they represent 0.9 % of genetic-
ally defined cases. This proportion increases to 4 % if we
consider the group of patients with onset before 10 years
of age (which is mainly patients with sarcoglycanopathies,
calpainopathies, and LGMD2I). Interestingly, GMPPB
mutations were absent from our cohort.
Overall, our patient carrying ISPD mutations pre-
sented a very mild LGMD phenotype compared with
other cases described in the literature. He presented
with early onset at 5 years of age with abnormal gait on
tiptoe, and complained of his first motor limitation (im-
pairment of his ability to run) at 14 years of age. Muscle
weakness demonstrated a slowly progressive course with
preserved independent ambulation at 42 years of age.
Motor performances in the previously reported ISPD-
mutated cases were variable, ranging from supported
standing to independent running [29]; however, loss of
independent ambulation (or ambulation for very short
distances) has been reported universally in patients who
had their last follow-up in adult age [28, 29]. In particu-
lar, the four cases of LGMD without central involvement
described by Cirak et al. [29] presented a more severe
Duchenne-like phenotype: they have early onset (1.5 to
3 years), higher creatine kinase levels, and severe pro-
gression (3 of 4 were non-ambulant at 12 years of age).
Regarding cardiac impairment in patients with mutated
ISPD, one adult patient exhibited a cardiac conduction
defect in a likely history of previous myocardic ischemia
[28], and three of four LGMD children described by
Cirak et al. exhibited decreased contractility without any
conduction defects [29]. Respiratory impairment has
been described in a minority of patients affected with
Fig. 4 Muscle biopsy analysis. Quadriceps muscle biopsy of the
patient with a mutation in the ISPD gene, performed at 4 years of
age. Diffuse variation in fiber size, basophilic regenerating fibers,
increased internal nuclei, hypercontracted fibers, and moderate
increase of endomysial connective tissue were shown, characterising
a typical dystrophic pattern (a haematoxylin and eosin, 20×). In the
same patient, α-DG IHC (b clone VIA4-1, 20×) revealed absence of
signal (c control muscle, 20×)
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CMD with α-dystroglycan deficiency [36, 38]; however,
decreased pulmonary volumes have been detected
among both paediatric and adult patients with ISPD mu-
tations [28, 29]. Interestingly, our patient did not exhibit
any cardiac or respiratory involvement and he was fully
ambulant in his forties, featuring the mildest symptoms
on the ISPD-mutated spectrum reported thus far. Fur-
thermore, our case confirms that absence of cognitive
impairment is common in patients with ISPD mutations
and LGMD phenotype [28, 29].
ISPD pathogenic mutations are generally located in
the first exons of the gene. Furthermore, LGMD pheno-
types are generally associated with milder mutations,
such as missense and in-frame mutations, compared
with CMD presentations.
In our patient, we detected two heterozygous muta-
tions located in the first exons, namely one missense
substitution and one intronic change that caused alter-
ation of splicing and production of an out-of-frame tran-
script. The missense mutation had also been described
in a foetal presentation with cobblestone lissencephaly,
in association with a large deletion of three exons (exons
4 through 6) [17]. We can argue that our patient’s
relatively mild phenotype is correlated with the compen-
satory action of other enzymes that have been implicated
in α-DG glycosylation.
Immunohistochemical analysis revealed a complete
absence of α-DG staining in our case. Among dystroglyca-
nopathies, good correlation between α-DG staining and
disease course was demonstrated in only a few forms
(POMT1, POMT2, and POMGnT1-mutated cases), and is
absent in patients with mutations in FKRP and FKTN
[39]. As previously reported, α-DG labelling was severely
reduced or absent in all patients with mutations in ISPD,
irrespective of clinical severity [13, 14, 28, 29]. Our case,
in whom clinical phenotype did not correlate with the
absence of α-DG, further supports this lack of correlation.
Conclusion
Overall, ISPD mutations are a rare cause of LGMD in
the Italian population, and account for approximately
1 % of our entire cohort of genetically characterised
LGMD (in comparison, FKRP mutations are responsible
for up to 8 %). If we consider patients with paediatric
onset, the frequency of LGMD2S increases to 4 % of
molecularly diagnosed forms. At the time of this writing,
no cases with adult onset have been reported. GMPPB
mutations were absent in our cohort. Furthermore, re-
duction of α-DG staining is not frequent among LGMD
cases; it accounts for only 11 % of biopsies from genetic-
ally undiagnosed patients. However, considering the
increasing number of genes involved in α-DG glycosyla-
tion and the genetic overlap between congenital muscu-
lar dystrophies and LGMD, α-DG IHC analysis should
be always performed in cases of undiagnosed LGMD in
order to detect reduction of the protein level, which can
then be investigated further.
Additional file
Additional file 1: Molecular characterization of the LGMD cohort.
The table illustrates the detailed molecular data of the 102 molecularly
diagnosed patients. (PDF 68 kb)
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